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Francisco Corzana, d Eufraˆnio N. da Silva Ju´nior, c Oliver Werzb
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Using machine learning, targets were identified for b-lapachone. Resorting to biochemical assays, b-
lapachone was validated as a potent, ligand efficient, allosteric and reversible modulator of 5-
lipoxygenase (5-LO). Moreover, we provide a rationale for 5-LO modulation and show that inhibition of
5-LO is relevant for the anticancer activity of b-lapachone. This work demonstrates the power of
machine intelligence to deconvolute complex phenotypes, as an alternative and/or complement to
chemoproteomics and as a viable general approach for systems pharmacology studies.Introduction
Natural products (NPs) provide inspiration for developing
disease-modulating chemical matter andmake up ca. 40% of all
approved drugs,1–3 but their use in molecular medicine is
declining.4 Despite progresses in synthetic methodologies to
provide scalable routes to NPs, their utility remains hampered
by limited knowledge of on-/off-targets that could explain
phenotypic effects and liabilities. In this regard, drug target
identication remains a daunting task in modern drug
discovery, which is oen tackled through chemoproteomics.5–9
Successful chemoproteomics requires tagging of ligands. Apart
from the identication of proper tagging sites and potentially
extensive synthetic work, ligand derivatization may severely
alter the binding affinity to on- and/or off-targets. Therefore,
machine intelligence for target identication, which does not
suffer from such drawbacks, is of high value.
b-Lapachone (1, Fig. 1) is a clinical-stage, natural naph-
thoquinone with antitumor activity once activated by NAD(P)
H:quinone oxireductase 1 (NQO1).10 Although bioactivation by
NQO1 results in anticancer activity,11 it is conceivable thatde Medicina da Universidade de Lisboa,
ugal. E-mail: tiago.rodrigues@medicina.
niversity Jena, Philosophenweg 14, D-
Chemistry, Federal University of Minas
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Cambridge, Lenseld Road, CB2 1EW
(ESI) available: Supplementary gures,
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hemistry 2018additional proteins are involved in the mode of action of 1.
Discovery of those proteins can constitute an important hall-
mark in the understanding of pharmacology networks for 1.
Additionally, it may leverage the development of b-lapachone-
based drug delivery systems to mask the much-acclaimed
drawbacks of naphthoquinones, while still affecting tumour
cell viability through hitherto unknown modes of action.
Herein, supported by a unique machine intelligence plat-
form and without resorting to NP tagging, we disclose that the
hydroquinone form of 1 is a potent and reversible modulator of
5-lipoxygenase (5-LO). Moreover, hydroquinone 1 binds to an
allosteric pocket with a unique molecular recognition pattern.
Crucially, we establish an unprecedented link between 5-LO
inhibition by 1 and its well-documented anticancer activity.Results and discussion
As part of our NP target identication program, we set out to
investigate the pharmacology of 1. We employed a machine
learning method (SPiDER)12,13 that uses a consensus of self-
organizing maps built from physicochemical and pharmaco-
phore features. Tessellation of the chemical feature spaceFig. 1 b-Lapachone, 1, may be present in the quinone or hydroqui-
none forms.
Chem. Sci., 2018, 9, 6899–6903 | 6899
Fig. 2 b-Lapachone, 1, inhibits human 5-lipoxygenase (5-LO). (a)
Inhibition of 5-LO in a cell-free assay in presence or absence of 1 mM
dithiothreitol (DTT). IC50 (with DTT) ¼ 0.24 mM  0.13 log units, n ¼ 3.
IC50 (without DTT) > 30 mM, n ¼ 3. Control: zileuton, IC50 ¼ 1 mM. (b)
Inhibition of 5-LO by 1 plus 1 mMDTT in presence or absence of 0.01%
Triton X100. IC50 (with Triton X100) ¼ 0.09 mM  0.21 log units, n ¼ 3;
IC50 (without Triton X100) ¼ 0.12 mM  0.14 log units, n ¼ 3. (c)
Inhibition of 5-LO activity in neutrophil homogenates in presence or
absence of 1 mM DTT. IC50 (with DTT) ¼ 0.09 mM  0.13 log units, n ¼
3; IC50 (without DTT) ¼ 5.2 mM  0.46 log units, n ¼ 3. Inhibition by
zileuton is independent of DTT.
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View Article Onlineprovides an intuitive means for data visualization and predic-
tion of potential drug target counterparts. In summary, co-
clustering of 1 with any given reference ligands suggests
a similar ligand–target relationship. Additionally, the method
calculates a p-like value to rank order qualitative predictions, i.e.
a binary bind/do not bind output. The approach had been
validated with NPs, to which new biology was inferred.5,7,13,14 In
contrast to other tools using structural ngerprints,15,16 several
targets were condently predicted for 1 with SPiDER12 (cf. ESI†).
From an algorithm standpoint, competing tools arguably
underperformed in this case due to the employed descriptors.
In fact, 1 presents a scaffold scarcely explored in target-based
screens, which impacts directly in tools using substructural
ngerprints, but not as prominently in SPiDER.
With condent SPiDER predictions in hand, we prioritized
228 kinases, 5-LO, and selected G-protein coupled receptors
(GPCRs) and transient receptor potential channels for addi-
tional analyses, since they had also been condently predicted
for lapachol – an isomer of 1 (cf. ESI†) – and downstream assays
were readily accessible. We sought additional prediction
condence by building the Drug–Target Relationship Predictor
(DEcRyPT) machine intelligence workow that uses regression
random forest technology as an orthogonal learning approach
to self-organizing maps. In doing so, we aimed at curating
condent predictions from SPiDER by estimating an affinity
value for 1 against the 236 pre-selected targets. DEcRyPT was
built using manually and automatically curated ChEMBL22
data to solely include relevant bioactivity information for model
assembly. The bioactivity annotations were normalized by
transforming the affinity data into a log10 value (pAffinity). The
CATS2 topological pharmacophore descriptors were then
calculated for each reference ligand (MOE, CCG Canada
implementation).17 In short, CATS2 combinatorially autocorre-
lates pharmacophore features within a molecule (positive/
negative charge, lipophilic, aromatic, hydrogen bond donor/
acceptor) up to a topological distance of 10 bonds. Given the
‘fuzziness’ of the molecular descriptor, the resulting high
dimensional vector can be used to leverage machine intelli-
gence in the absence of apparent ligand structure similarity,
which is arguably ideal for both de novo designed compounds12
and NPs.18 The built models were subjected to stratied 10-fold
cross-validation to assess quality. An average mean absolute
error of 0.533 0.103 log units suggests the general utility of the
computed models. Moreover, the models support a range of
different activities for 1, providing complementary information
to clustering algorithms, such as SPiDER, and further allowing
screening prioritizations.
We screened 1 against 45 kinases, 4 GPCRs (EP1–4), 2 tran-
sient receptor potential channels (TRPV1 and TRPM8), and 1
enzyme (5-LO) using functional assays. At a single concentra-
tion (150 mM; cf. ESI†), we found that 1 interfered with the
kinase assay technology and presented only weak TRP channel
effects. Also in agreement with DEcRyPT, 1 presented potent
activity against EP3 and 5-LO, especially in the latter case.
Crucially, the observed range of activities against unrelated
proteins suggests specic target recognition (cf. ESI†). In fact, 1
displayed concentration-dependent effects against 5-LO and6900 | Chem. Sci., 2018, 9, 6899–6903ligand efficiency >0.30, indicating that potent entities inspired
by its scaffold may be obtained via medicinal chemistry.
Compound 1 potently inhibited 5-LO in a cell-free functional
assay and in reducing conditions (IC50 ¼ 0.24 mM  0.13 log
units; Fig. 2a; Table 1). An orthogonal 5-LO functional assay
corroborated the obtained data (cf. ESI†). Albeit more modest, 1
inhibited EP3 with potency identical to that predicted by
DEcRyPT. Our data thus show the accuracy and general utility of
our method for the prediction of target affinities. Signicantly,
no aggregation of 1, which could lead to artefactual readouts,
was measured through dynamic light scattering at relevant
concentrations (cf. ESI†). The presence or absence of 0.01%
Triton X100 also led to identical concentration-response curves
in cell-free 5-LO inhibition assays (Fig. 2b), which again rules
out unspecic interference by 1. We then analysed 5-LO inhi-
bition in intact human neutrophils stimulated with A23187 and
exogenous arachidonic acid to assess the efficiency of 1 as
a leukotriene biosynthesis inhibitor.19 b-Lapachone suppressed
5-LO product formation with an IC50 value of 8.6 mM  0.10 log
units (cf. ESI†). The reduced potency of 1 in inhibiting 5-LO
product formation in neutrophils could be due to hampered
cellular uptake of the compound or competition with endoge-
nous factors. Still, when supplementing neutrophils with 1 mM
dithiothreitol, 1 inhibited 5-LO with an IC50 value of 0.42 mM 
0.10 log units (cf. ESI†), which is in accordance with data from
the cell-free assay. Thus, 1 is likely not fully reduced in the
native neutrophil environment. Moreover, 1 potently inhibited
5-LO in neutrophil homogenates with 1 mM dithiothreitol with
an IC50 value of 85.5 nM  0.13 log units (Fig. 2c), in line with
the cell-free 5-LO assay.
To probe for metalloenzyme selectivity, we screened 1
against 12-LO and 15-LO using two different methods. Weak
inhibition (IC50 > 30 mM) was obtained in both cases, which
highlights selectivity of 1 for 5-LO (cf. ESI†). Screening against
the solvent-exposed Zn2+-containing phosphodiesterase 5
(PDE5) also revealed inactivity, suggesting that 1 is not a general
metal chelator (Table 1). Overall, we provide robust evidence
that 1 is a true 5-LO inhibitor. Notably, the scaffold of 1 is notThis journal is © The Royal Society of Chemistry 2018
Table 1 Affinity predictions with DEcRyPT for b-lapachone
Target name Predictiona MAEb Experimentalc
Kinases (n ¼ 228) <4.0–6.4 0.268–0.925 n.d.
5-LO 4.5 0.427 6.6d, 5.6e
TRPV1 <4.0 0.556 4.0
TRPM8 <4.0 0.465 <4.0
EP1 <4.0 0.745 <4.0
EP2 5.3 0.487 4.0
EP3 5.1 0.507 4.7
EP4 4.4 0.591 4.0
PDE5 <4.0 0.642 <5.0
a Prediction ¼ pAffinity  variance; where pAffiinty log(IC/EC50, KD/i).
b Mean absolute error. c log(IC50 or KD). d Metabolite detection
assay. e Indirect uorogenic readout. n.d. ¼ not determined due to
assay interference.
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View Article Onlineexploited among 5-LO ligands despite preserving the pharma-
cophore features for target engagement (cf. ESI†). Thus, simi-
larity searches with commonly used ngerprints would likely
fail in identifying the 1–5-LO relationship despite the existence
of other ortho-quinone 5-LO inhibitors, i.e. the ligand–target
association is non-obvious. To further probe the specic 5-LO
recognition we expanded our hit by synthesizing a focused
library of racemic b-lapachone-inspired entities (Fig. 3a).
Generally, the in situ bromination of an appropriate starting
material afforded the respective key intermediates, which were
subsequently functionalized with the required nucleophilic
species.20–22 A range of inhibition potencies were obtained for
racemic mixtures of compounds 2–8 in cell-free 5-LO assays,
supporting the importance of the substitution pattern for
bioactivity and the specic, directed interactions of 1 with 5-LO
(Fig. 3b).
To understand themolecular basis of 5-LO inhibition by 1we
conducted the cell-free functional assay in the absence of
dithiothreitol, which led to negligible 5-LO modulation up to
a concentration of 30 mM (Fig. 2a). From a learning algorithm
point of view the result is puzzling as the drug target predictions
were carried out with ortho-quinone 1. However, it is possibleFig. 3 Focused library of b-lapachone-inspired entities. (a) Structures
of the synthesized analogues 2–8. (b) Relative inhibitory activities
against 5-LO (cell-free assay, Cerep, France) at 5 mM, n¼ 2. Bars depict
the range.
This journal is © The Royal Society of Chemistry 2018that the active species are ill-annotated for a fraction of
quinone/ortho-quinone 5-LO inhibitors included in ChEMBL22
and that were used as training dataset; this can justify the
prediction outcome. Nonetheless, our machine intelligence is
able to condently predict hydroquinone 1 as a 5-LOmodulator.
In a broader perspective, the obtained result underscores the
need to better prole quinones whenever found active in func-
tional assays. The enzymatic result was also reproducible with
homogenized human neutrophils, i.e.without dithiothreitol the
inhibitory potency of 1 is sharply reduced (IC50 ¼ 0.085 mM vs.
5.2 mM, Fig. 2c). Hence, our data not only shows that hydro-
quinone 1 is the active species against 5-LO, but also reinforces
there is insufficient hydroquinone formation within neutro-
phils. However, from an anticancer activity standpoint, the
marked reducing environment within cancer cells and micro-
environment, e.g. through glutathione or NQO1, may present
the ideal setting for phenotype modulation by 1 in cells with 5-
LO overexpression. Next, we conrmed that activity of 5-LO
could be reinstated upon wash-out of 1, and that a variation of
arachidonic acid concentration (2.5–40 mM) led only to minor
alterations of the potency of 1 (cf. ESI†). Taken together, our
data robustly advocates for a reversible and allosteric modula-
tion of 5-LO by hydroquinone 1, as a potential means for
mediating the anticancer activity.23 This result not only agrees
with the absence of modulation of related (12-/15-LO) and
unrelated (PDE5) metal-containing targets, but also contrasts
with a report suggesting chelation of the Fe3+ centre in IDO1.24
To obtain insights into the putative binding mode of
hydroquinone 1, we built a homology model for the wild type 5-
LO using the apo mutant structure as template (Fig. 4a and b).
We then predicted binding pockets with volume > 110 A˚3, given
that only a small fraction of pockets with smaller volumes
accommodate ligands (Fig. 4c).25 Several 5-LO ligands have been
predicted to sit in an allosteric site at the C2-like and catalytic
domains' interface25 – a region well known to accommodate
phospholipids and being critical for 5-LO function and
dynamics.26,27 Supported by our data and literature, we docked
hydroquinone 1 with GOLD28 into this predicted site (Fig. 4d).
The resulting model suggests that hydroquinone 1 binds
through hydrogen bonds to D170, R401 and E622, and performs
an amide–p stacking with Q12 (Fig. 4e), at the C2-like and
catalytic domains' interface. Disruption of the C2–catalytic
domain interaction is known to increase 5-LO activity,29 which
can be counteracted by hydroquinone 1. Moreover, molecular
docking of a select enantiomeric pair suggests that molecular
recognition is sensitive to stereogenic centre conguration and
that future study of enantiopure entities may provide 5-LO-
tailored inhibitors (cf. ESI†). We next performed competition
assays between 1 and phosphatidylcholine, which binds to the
predicted groove. Increasing concentrations of phosphatidyl-
choline promote the 5-LO product formation (cf. ESI†) and
markedly diminish the 5-LO blocking efficiency of hydroqui-
none 1 (Fig. 4f), providing evidence for competitive binding.
Furthermore, the alignment of 5-LO, 12-LO and 15-LO (Fig. 4g)
sequences shows dissimilarities in the predicted binding
pocket region, which may partly explain the weak effects of 1
against the latter two. Altogether, the excellent agreementChem. Sci., 2018, 9, 6899–6903 | 6901
Fig. 4 Bindingmodel of hydroquinone 1 to 5-lipoxygenase (5-LO) and relationship with the anticancer activity. (a) Mutant 5-LO used as template
(PDB 3V98). (b) Homology model of wild-type human 5-LO. (c) Predicted binding pockets with volume > 110 A˚3. (d) Docking pose of hydro-
quinone 1 into the predicted allosteric pocket. (e) Detail of the predicted interactions between 1 and 5-LO. (f) Competition assay (IC50 curve)
between 1 and phosphatidylcholine (PC), n ¼ 3. IC50 (3 mg mL1, PC) ¼ 100 nM; IC50 (30 mg mL1, PC) ¼ 1000 nM. Data advocates for
a competition event. (g) Sequence alignment between 5-, 12- and 15-LO. Orange: full match; blue: partial match. Residue counterparts for
hydroquinone 1 are highlighted in orange boxes. (h) 5-LO protein expression. Control: HL-60 cells; differentiated: DMSO-stimulated HL-60 cells.
(i) IC50 values for 1 against both HL-60 cell line groups. IC50 (differentiated)¼ 0.18 mM; IC50 (control)¼ 0.39 mM, n¼ 1. (j) Percentage of live HL-60
cells in the differentiated and control groups when treated with 0.5 mM of 1, n ¼ 3. Statistics: two-tailed t-Student test; **p < 0.005.
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View Article Onlinebetween the in silico models and biochemical data suggests
a direct interaction between hydroquinone 1 and 5-LO, through
a hitherto unknown allosteric recognition mechanism at the
C2–catalytic domains' interface. Finally, to ascertain the
importance of allosteric binding and 5-LO inhibition for the
anticancer activity of 1 we conducted cell-viability assays with
the HL-60 cell line. This leukemia cell line does not overexpress
5-LO except when differentiated (Fig. 4h and ESI†).30,31 Treat-
ment of both groups with 1 showed that cells overexpressing 5-
LO were more sensitive than the control (Fig. 4i and ESI†),
displaying IC50 values of 0.18 mM and 0.39 mM, respectively.Fig. 5 Proposed mechanism of anticancer activity of b-lapachone. b-
Lapachone is reduced in situ by NQO1 (or glutathione) to the corre-
sponding hydroquinone form, which inhibits 5-lipoxygenase (5-LO)
and elicits cancer cell death. b-Lapachone and its hydroquinone form
may present additional drug targets and form reactive oxygen species
(ROS) that, together with 5-LO, contribute to the overall phenotypic
effects.
6902 | Chem. Sci., 2018, 9, 6899–6903Indeed, the result is statistically signicant (Fig. 4j), which
endorses 5-LO as an anticancer target for 1 in vitro (Fig. 5). The
result ultimately conrms our hypothesis that in cancer cells
the strongly reducing environment efficiently generates hydro-
quinone 1 for 5-LO modulation.Conclusions
Herein, we provide innovative machine intelligence to decon-
volute targets of phenotypic hits and accurately predict affini-
ties. However, DEcRyPT presents caveats; it depends on several
high-quality positive/negative data points, spanning a wide
range of activities for model building. These requirements are
not met for ChEMBL targets that were discarded from DEcRyPT.
Still, interpreting the output of an ensemble of decision trees is
intuitive for chemists and biologists, to whom suchmodels may
be useful. Moreover, random forests do not require data pre-
processing, e.g. scaling descriptors. These are considerable
advantages compared to other algorithms, including deep
neural networks. The results also suggest that sparse topolog-
ical pharmacophores efficiently encode target relationships
between similar ligands.
Despite numerous reports and studies on the biology of 1
and high interest in 5-LO over the past two decades, no asso-
ciation between them had been established by expert
researchers. The machine intelligence platform described here
was key to unravel this unprecedented link. We thoroughly
validate allosteric inhibition of 5-LO by hydroquinone 1 and
disclose its signicance in a cancer cell line. Thus, further
studies on the compound–target–disease relationship are war-
ranted. These studies might be daunting, considering the
challenges of developing naphthoquinones as therapeutics; one
must consider that 1 perturbs multiple targets, some of whichThis journal is © The Royal Society of Chemistry 2018
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View Article Onlineremain unknown. Nonetheless, we provide proof-of-concept
that smart computational technologies can effectively advance
early natural product-based drug discovery, be a swi alterna-
tive to chemoproteomics and work as a general strategy for
systems pharmacology studies.Conflicts of interest
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